K. O’boyle

发表

An in vitro approach to assessing a potential drug interaction between MDMA (ecstasy) and caffeine.

C. Downey, F. Daly, K. O’boyle, 2014, Toxicology in vitro : an international journal published in association with BIBRA.

Synthesis of a glucuronic acid and glucose conjugate library and evaluation of effects on endothelial cell growth.

P. Murphy, Stephen J. Wilson, N. Pitt, 2004, Carbohydrate research.

Hybrids of 1-deoxynojirimycin and aryl-1,2,3-triazoles and biological studies related to angiogenesis.

P. Murphy, Yunxue Zhao, K. O’boyle, 2008, Bioorganic & medicinal chemistry.

N-Glycosyl-thiophene-2-carboxamides: effects on endothelial cell growth in the presence and absence of bFGF--a significant increase in potency using per-O-acetylated sugar analogues.

V. Zaric, P. Murphy, K. O’boyle, 2006, Bioorganic & medicinal chemistry letters.

D2 receptor‐mediated inhibition of dopamine release in the rat striatum in vitro is modulated by CB1 receptors: studies using fast cyclic voltammetry

J. O'connor, K. O’boyle, C. O'Neill, 2009, Journal of neurochemistry.

Synthesis of disaccharides derived from heparin and evaluation of effects on endothelial cell growth and on binding of heparin to FGF-2.

P. Murphy, Alan O'Brien, K. O’boyle, 2004, Carbohydrate research.

[3H]SCH 23390 Binding to Human Putamen D‐1 Dopamine Receptors: Stereochemical and Structure‐Affinity Relationships Among l‐Phenyl‐1H‐3‐Benzazepine Derivatives as a Guide to D‐l Receptor Topography

J. Waddington, K. O’boyle, 1987, Journal of neurochemistry.

Identification of novel inhibitors of fibroblast growth factor (FGF-2) binding to heparin and endothelial cell survival from a structurally diverse carbohybrid library.

P. Murphy, Stephen J. Wilson, N. Pitt, 2002, Bioorganic & medicinal chemistry letters.

Association of intellectual impairment, negative symptoms, and aging with tardive dyskinesia: clinical and animal studies.

J. Waddington, A. Molloy, H. Youssef, 1985, The Journal of clinical psychiatry.

Royal Academy of Medicine in Ireland Section of Biomedical Sciences

C. Scholfield, T. Curtis, S. McDonough, 1999 .

Pharmacologically distinct binding sites in rat brain for [3H]thyrotropin-releasing hormone (TRH) and [3H][3-methyl-histidine(2)]TRH.

J. A. Kelly, K. O’boyle, G. R. Slator, 2002, Biochemical pharmacology.

Loss of rat striatal dopamine receptors with ageing is selective for D-2 but not D-1 sites: association with increased non-specific binding of the D-1 ligand [3H]piflutixol.

J. Waddington, K. O’boyle, 1984, European journal of pharmacology.

A novel TRH analog, Glp–Asn–Pro–d-Tyr–d-TrpNH2, binds to [3H][3-Me-His2]TRH-labelled sites in rat hippocampus and cortex but not pituitary or heterologous cells expressing TRHR1 or TRHR2

P. M. Hinkle, J. A. Kelly, K. O’boyle, 2008, Neuroscience Letters.

Agonist and antagonist interactions with D1 dopamine receptors: Agonist-induced masking of D1 receptors depends on intrinsic activity

J. Waddington, K. O’boyle, 1992, Neuropharmacology.

Effects of the putative D-1 antagonist SCH 23390 on stereotyped behaviour induced by the D-2 agonist RU24213

J. Waddington, A. Molloy, K. O’boyle, 2004, Psychopharmacology.

A re-evaluation of changes in rat striatal D-2 dopamine receptors during development and aging

J. Waddington, K. O’boyle, 1986, Neurobiology of Aging.

Drugs acting on brain dopamine receptors: a conceptual re-evaluation five years after the first selective D-1 antagonist.

J. Waddington, K. O’boyle, John L. Waddington, 1989, Pharmacology & therapeutics.

Nefiracetam (DM-9384) reverses apomorphine-induced amnesia of a passive avoidance response: Delayed emergence of the memory retention effects

C. Regan, E. Doyle, K. O’boyle, 1996, Neurochemical Research.

Structural determinants of selective affinity for brain D-1 dopamine receptors within a series of 1-phenyl-1H-3-benzazepine analogues of SK&F 38393 and SCH 23390.

J. Waddington, K. O’boyle, 1985, European journal of pharmacology.

Enantiomeric analogues of SCH 23390 as new probes for behavioral interactions between D1 and D2 dopaminergic function.

J. Waddington, A. Molloy, K. O’boyle, 1986, Advances in experimental medicine and biology.

Royal Academy of Medicine in Ireland Section of Biomedical Sciences

C. G. Lyons, B. Schreiber, R. Huiskes, 1997 .

Behavioural pharmacology op ‘D-1-like’ dopamine receptors: Further subtyping, new pharmacological probes and interactions with ‘D-2-like’ receptors

S. A. Daly, J. Waddington, K. O’boyle, 1995, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Royal academy of medicine in Ireland section of biomedical sciences Proceedings of Summer Meeting held June, 1994

D. Egan, O. Hardiman, J. Kelly, 1994 .

Cholinergic activation of Cl- secretion in rat colonic epithelia.

A. Baird, C. Farrell, K. E. O'malley, 1995, European journal of pharmacology.

First-in-class thyrotropin-releasing hormone ( TRH )-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models

David J Brayden, D. Mash, O. Hardiman, 2014 .

Behavioural, hyperthermic and neurotoxic effects of 3,4-methylenedioxymethamphetamine analogues in the wistar rat

John P. Kelly, J. Kelly, G. Boland, 2001, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

The D-1 Dopamine Receptor and the Search for its Functional Role: From Neurochemistry to Behaviour

J. Waddington, K. O’boyle, 1987, Reviews in the neurosciences.

Dopamine-induced reduction in the density of guanine nucleotide-sensitive D1 receptors in human postmortem brain in the absence of apparent D1: D2 interactions

J. Waddington, K. O’boyle, P. G. McCauley, 1995, Neuropharmacology.

Agonist and antagonist properties of benzazepine and thienopyridine derivatives at the D1 dopamine receptor

J. Waddington, D. Gaitanopoulos, K. O’boyle, 1989, Neuropharmacology.

Selective and stereospecific interactions of R-SK & F 38393 with [3H]piflutixol but not [3H]spiperone binding to striatal D1 and D2 dopamine receptors: comparisons with SCH 23390.

J. Waddington, K. O’boyle, 1984, European journal of pharmacology.

Locomotor behaviors in response to new selective D-1 and D-2 dopamine receptor agonists, and the influence of selective antagonists

J. Waddington, A. Molloy, K. O’boyle, 1986, Pharmacology Biochemistry and Behavior.

Discovery of a dual action first-in-class peptide that mimics and enhances CNS-mediated actions of thyrotropin-releasing hormone

K. Tipton, D. Gregg, P. M. Hinkle, 2007, Neuropharmacology.

The kinetics of [3H]SCH 23390 dissociation from rat striatal dopamine D1 receptors: effect of dopamine.

C. Farrell, K. O’boyle, Kathy M. O'Boyle, 1994, European journal of pharmacology.

Corrigendum to “A novel TRH analog, Glp–Asn–Pro–d-Tyr–d-TrpNH2, binds to [3H][3-Me-His2]TRH-labelled sites in rat hippocampus and cortex but not pituitary or heterologous cells expressing TRHR1 or TRHR2” [Neurosci. Lett. 431 (2007) 26–30]

P. M. Hinkle, J. A. Kelly, K. O’boyle, 2008, Neuroscience Letters.

New substituted 1-phenyl-3-benzazepine analogues of SK&F 38393 and N-methyl-thienopyridine analogues of dihydroxynomifensine with selective affinity for the D-1 dopamine receptor in human post-mortem brain

J. Waddington, K. O’boyle, 1987, Neuropharmacology.

New Selective D-1 and D-2 Dopamine Receptor Agonists as Further Probes for Behavioural Interactions between D-1 and D-2 Systems

J. Waddington, K. O’boyle, A. M. Murray, 1988 .

Identification of the enantiomers of SK&F 83566 as specific and stereoselective antagonists at the striatal D-1 dopamine receptor: comparisons with the D-2 enantioselectivity of Ro 22-1319.

J. Waddington, K. O’boyle, 1984, European journal of pharmacology.

Adenosine A1 receptor‐mediated inhibition of dopamine release from rat striatal slices is modulated by D1 dopamine receptors

K. O’boyle, C. O'Neill, J. O’Connor, 2007, The European journal of neuroscience.

Functional coupling of a recombinant Human 5‐HT5A receptor to G‐proteins in HEK‐293 cells

F. Martin, M. Rogers, R. A. McMahon, 1998, British journal of pharmacology.

D2 receptor agonists and partial agonists: relationship between receptor binding measures and functional activity.

M. Lawler, K. O’boyle, 1996, Biochemical Society transactions.

Motor consequences of D-1 dopamine receptor stimulation and blockade.

J. Waddington, A. Molloy, K. O’boyle, 1986, Clinical neuropharmacology.

First-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models

David J Brayden, D. Mash, O. Hardiman, 2015, Neuropharmacology.

Effects of a combination of 3,4-methylenedioxymeth amphetamine and caffeine on real time stimulated dopamine release in the rat striatum: Studies using fast cyclic voltammetry

J. Lowry, K. O’boyle, J. O'Connor, 2017, Journal of Neuroscience Methods.